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Edited by Sandro SonninoAbstract Protein-mediated LCFA transport across plasma
membranes is highly regulated by the fatty acid transporters
FAT/CD36 and FABPpm. Physiologic stimuli (insulin stimula-
tion, AMP kinase activation) induce the translocation of one
or both transporters to the plasma membrane and increase the
rate of LCFA transport. In the hypoxic/ischemic heart, intramy-
ocardial lipid accumulation has been attributed to a reduced rate
of fatty acid oxidation. However, since acute hypoxia (15 min)
activates AMPK, we examined whether an increased
accumulation of intramyocardial lipid during hypoxia was also
attributable to an increased rate of LCFA uptake as a result
AMPK-induced translocation of FAT/CD36 and FABPpm. In
cardiac myocytes, hypoxia (15 min) induced the redistribution
of FAT/CD36 from an intracellular pool (LDM) (25%,
P < 0.05) to the plasma membranes (PM) (+54%, P < 0.05).
Hypoxia also induced an increase in FABPpm at the PM
(+56%, P < 0.05) and a concomitant FABPpm reduction in the
LDM (24%, P < 0.05). Similarly, in intact, Langendorﬀ per-
fused hearts, hypoxia induced the translocation of a both FAT/
CD36 and FABPpm to the PM (+66% and +61%, respectively,
P < 0.05), with a concomitant decline in FAT/CD36 and FAB-
Ppm in the LDM (24% and 23%, respectively, P < 0.05).
Importantly, the increased plasmalemmal content of these
transporters was associated with increases in the initial rates
of palmitate uptake into cardiac myocytes (+40%, P < 0.05).
Acute hypoxia also redirected palmitate into intracellular lipid
pools, mainly to PL and TG (+48% and +28%, respectively,
P < 0.05), while fatty acid oxidation was reduced (35%,
P < 0.05). Thus, our data indicate that the increased intracellu-
lar lipid accumulation in hypoxic hearts is attributable to both:
(a) a reduced rate of fatty acid oxidation and (b) an increased
rate of fatty acid transport into the heart, the latter being
attributable to a hypoxia-induced translocation of fatty acid
transporters.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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In the well-oxygenated heart, long chain fatty acids (LCFAs)
are the preferred source of energy, accounting for 80% of its
oxidation [1]. Because there is limited capacity for lipid storage
in cardiac myocytes, the uptake and oxidation of fatty acids
are tightly coupled. An accumulation of excess lipid within car-
diac myocytes can occur when the rate of fatty acid uptake ex-
ceeds the rate of fatty acid oxidation, as has been observed in
heart of obese Zucker rats [2]. Recently it was shown that lipid
accumulation might be a signiﬁcant feature of heart failure [3].
The reason seems to be that intramyocardial lipid overload sig-
niﬁcantly contributes to contractile dysfunction [4] and
arrhythmias [5].
LCFAs are known to be taken up by cells through passive
diﬀusion [6,7]. However recent evidence has also shown that
LCFA uptake is also facilitated by a protein-mediated mecha-
nism [8–10]. Speciﬁcally, the plasmalemmal abundance of
LCFA transporters determines the cellular capacity for fatty
acid uptake in tissues that are highly dependent on lipid utili-
zation [10–12]. Key LCFA transport proteins in heart include
fatty acid translocase, the homolog of CD36 (FAT/CD36) and
plasma membrane associated fatty acid binding protein FAB-
Ppm. Recent studies have shown that when the needs for en-
ergy are challenged in cardiac myocytes the rates of LCFA
transport are upregulated, due to the translocation of FAT/
CD36 from its intracellular depot to the plasma membrane
[13–15]. However, it has now also been shown that a second
fatty acid transporter, namely FABPpm, can be translocated
from its intracellular pool(s) to the sarcolemma [16]. Interest-
ingly, activation of speciﬁc signalling pathways selectively in-
duces the translocation of FAT/CD36 and FABPpm. In
cardiac myocytes insulin stimulation (activation of PI3K path-
way) induced only FAT/CD36 to translocate to the sarco-
lemma, whereas stimulation with AICAR (activation of
AMPK pathway) induced both FAT/CD36 and FABPpm to
be translocated to the plasma membrane [16].
It is well known that during myocardial ischemia fatty acids
are diverted from b-oxidation into the myocardial lipids depots
[17–19]. Nevertheless, the exact mechanism leading to lipid
deposition in ischemic cardiac tissue may however be more
complex than simply a reduced ability to oxidize fatty acids.
Under normal oxygen-supply conditions, AMPK activation
results in an increased rate of fatty acid oxidation [20–22],
which is supported by a concomitantly increased rate of fattyblished by Elsevier B.V. All rights reserved.
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cess is facilitated by FAT/CD36 and FABPpm, which are in-
duced to translocate to the plasma membrane, when AMPK
is activated pharmacologically [15,16]. AMPK is also activated
when oxygen availability is reduced in the heart or skeletal
muscle, because of the increase in AMP/ATP ratio [23,24]. Un-
der these circumstances intramyocardial lipids could accumu-
late rapidly, not only because of: (a) a reduced rate of fatty
acid oxidation, as has previously been suggested [17,18] but
(b) also due to an increased rate of fatty acid transport, as a
result of the AMPK-induced translocation of FAT/CD36
and FABPpm to the cell surface. Therefore, we investigated
the eﬀects of acute hypoxia (15 min) on the rates of fatty acid
transport and metabolism, and on the subcellular distribution
of the fatty acid transporters FAT/CD36 and FABPpm.2. Materials and methods
2.1. Materials
FAT/CD36 and FABPpm were detected using the MO25 antibody
[25] and FABPpm antisera [26], respectively. [1-14C]-palmitate and
[3H]-palmitate were purchased from Amersham Life Science (Little
Chalfont, UK). BSA (fraction V, essentially FA free) and phloretin
were obtained from Sigma–Aldrich (St. Louis, MO). Collagenase type
II was purchased from Worthington (Lakewood, NJ, USA). Phos-
phorylated quantities of selected proteins were determined with com-
mercially available antibodies phospho-Akt1/2/3 (Ser473), Santa
Cruz Biotechnology, (Santa Cruz, CA), phospho-ERK1/2 (Thr202/
Thr204) and phospho-AMPK (Thr172), Cell Signaling Technology
(Beverly, MA). Appropriate secondary antibodies were purchased
from Santa Cruz Biotechnology. All other chemicals were obtained
from Sigma–Aldrich. Male Wistar rats (250–300 g) were bred on site
and maintained at 20 C on a reverse light–dark cycle in approved
animal holding facilities. They had unrestricted access to food and
water. This study was approved by the committee on animal care at
the University of Guelph and at the Medical University of Bialystok,
respectively.
2.2. Methods
2.2.1. Initial rates of palmitate uptake and palmitate metabolism
Initial rate of palmitate uptake by cardiac myocytes. To examine ini-
tial rates of palmitate uptake it is necessary to use cardiac myocytes
[13–16]. Preparation of cardiac myocytes was performed as we have
previously described [13–16]. Brieﬂy, rats were anaesthetized using
Somnotol (50–60 mg/100 g, i.p.) combined with heparin (300 i.u./
100 g, i.p.). The hearts were quickly removed and placed in ice-cold
Krebs–Henseleit bicarbonate buﬀer, (KHB, pH 7.4), and equilibrated
with 95% O2 and 5% CO2. Subsequently, hearts were perfused
(20 min) in a recirculating mode, with KHB buﬀer supplemented with
0.7% (w/v) BSA, 15 mM butanedione monoxime and 0.075% (w/v)
collagenase type II. CaCl2 was added to a ﬁnal concentration
0.2 mM during the perfusion. After 20 min hearts were removed and
gently minced. The suspension was incubated for another 10 min at
37 C, while CaCl2 concentration was gradually raised to 1.0 mM.
Then cells were ﬁltered through 0.2 mm nylon gauze and centrifuged
for 2 min at 20 · g. After isolation, cells were washed twice and sus-
pended in 20 ml of medium A (KHB buﬀer supplemented with 2%
(w/v) BSA at a ﬁnal palmitate concentration 100 lM, (palmitate/
BSA ratio of 0.3) and 1 mM CaCl2). At the beginning of the experi-
ments the percentage of rod-shaped cells excluding trypan blue was
determined. For all the experiments P 80% of the cardiac myocytes
were structurally intact. For determination of cardiac myocytes wet
mass, duplicate aliquots of the cell suspensions were centrifuged
(2–3 s, at 10000 · g). The yield of cardiac myocytes ranged from 500
to 600 mg per single heart.
After isolation, cardiac myocytes were incubated in medium A for
15 min, continually gassed with 95% O2 and 5% CO2 or with 95%
N2 and 5% CO2, and during the last 3 min of the incubation a
[1-14C]-palmitate (100 lmol/l with a corresponding palmitate-to-BSAratio of 0.3)-BSA complex was added. Palmitate uptake was stopped
by adding an ice-cold stop solution (KHB buﬀer supplemented with
0.1% BSA (w/v), 1 mM CaCl2 and 0.2 mM phloretin). Subsequently,
cells were washed twice with the stop solution at 60 · g for 2 min.
The ﬁnal pellet was assayed for radioactivity.
Palmitate oxidation and incorporation into diﬀerent lipid pools. To
examine the eﬀects of hypoxia on palmitate metabolism, we used intact
hearts that were perfused in the Langendorﬀ perfusion mode. After
removing hearts from anaesthetized (Somnotol (50–60 mg/100 g, i.p.)
combined with heparin (300 i.u./100 g, i.p.)), hearts were perfused for
5 min equilibration period with KHB, hearts were switched to medium
A containing 3H-palmitate (100 lmol/l with a corresponding palmi-
tate-to-BSA ratio of 0.3) and continuously gassed for 15 min under
either normoxic (95% O2 and 5% CO2) or hypoxic (95% N2 and 5%
CO2) conditions. Thereafter, hearts were removed and immediately
freeze-clamped in liquid nitrogen and stored at 80 C until analyzed.
Heart lipids were extracted according to van der Vusse et al. [27], with
modiﬁcation as we previously described [28]. Brieﬂy, frozen heart sam-
ples were pulverized in an aluminium mortar with a stainless steel pes-
tle, both pre-cooled in liquid nitrogen. The powder was transferred
into glass tubes containing 2 ml of methanol at 20 C. Subsequently,
4 ml of chloroform was added. Lipids from chloroform layer were sep-
arated into diﬀerent fractions by means of thin-layer chromatography
(silica plate 60, 0.25 mm, Merck) using heptane:isopropyl ether:acetic
acid (60:40:3, v/v/v) (for TG, DAG, MG and PL separation). The total
lipid extract was also separated by TLC with hexane:diethyl ether:ace-
tic acid (10:90:1 vol/vol/vol) (for ceramide). After drying, the plates
were sprayed with a 0.2% solution of 2 07 0-dichloroﬂuorescein in meth-
anol and exposed shortly to ammonia vapours. The lipid bands, local-
ized under UV light and identiﬁed according to the standards (Sigma),
were scraped oﬀ the plates. Finally, samples were dissolved in hexane
and the 3H-palmitate incorporated into diﬀerent lipid pools was
determined.
Exogenous oxidation rates of 3H-palmitate were determined by mea-
suring the release of 3H2O into the perfusate buﬀer. The validity of
using rates of 3H2O production from
3H-palmitate as a measure of
exogenous palmitate oxidation has been previously described [29]. In
brief, 3H2O was separated from
3H-palmitate by treating 0.5 ml buﬀer
samples with a mixture of chloroform and 2 M KCl:HCl solution. The
aqueous phase was then collected and subsequently treated with a mix-
ture of chloroform, methanol and KCl:HCl (1:1:0.9 vol/vol/vol). Sub-
sequently, the aqueous phase was removed and counted for
radioactivity. This technique results in an extraction and separation
of 3H2O from
3H-palmitate, as has been reported previously [29].
Glycogen utilization. To examine the eﬀects of hypoxia on glycogen
utilization, we used intact hearts that were perfused in the Langendorﬀ
perfusion mode. Hearts were perfused for 5 min equilibration period
with KHB and afterwards hearts were switched to medium A
containing non-labeled palmitate conjugated with BSA (ﬁnal palmitate
concentration 100 lM, palmitate/BSA ratio of 0.3) and continuously
gassed for 15 min under either normoxic (95% O2 and 5% CO2) or
hypoxic (95% N2 and 5% CO2) conditions. Thereafter, hearts were
removed and tissue glycogen was determined accordingly [30]. Brieﬂy,
hearts were digested for 20 min in hot 30% KOH and subsequently, a
spectrophotometric assay was used to determine the content of
free glucose. Glycogen level is expressed in lmol of glucose/g of
tissue.
2.2.2. Subcellular fractionation of intact perfused hearts and cardiac
myocytes. To relate changes in the initial rates in palmitate uptake in
cardiac myocytes and in palmitate metabolism in perfused hearts, we
examined the subcellular distribution of fatty acid transporters in car-
diac myocytes and in perfused hearts. For these purposes control and
hypoxic hearts and cardiac myocytes were prepared as described
above, frozen in liquid nitrogen and stored at 80 C until analyzed.
Subcellular fractionation of cardiac myocytes. Subcellular fraction-
ation of control and hypoxic cardiac myocytes was performed as we
have described previously [13–16,31]. Brieﬂy, at the end of incubation
NaN3 was added (ﬁnal concentration 5 mM). Collected cardiac myo-
cytes were frozen in liquid N2, and kept at 80 C until analyzed.
To detect the subcellular distribution of fatty acid transporters, plasma
membranes (PM) and low density microsomes (LDM) were isolated
from cardiac myocytes [13–16,31]. We have previously examined the
purity of the fractionation procedure in which we characterized PM
and LDM fractions using immunoblotting and enzymatic measure-
ments [13–16].
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tionation of control and hypoxic Langendorﬀ perfused hearts was per-
formed using procedures previously described [32]. Upon thawing,
hearts were diced and incubated for 30 min in a high-salt solution
(2 mol/l NaCl, 20 mmol/l HEPES pH 7.4, and 5 mmol/l NaN3) at
4 C as recommended by Fuller et al. [32]. Thereafter, the suspension
was centrifuged for 5 min at 1000 · g and the pellet homogenized in
6.0 ml TES-buﬀer using a tightly ﬁtting 10-ml Potter-Elvejhem glass
homogenizer with 10 strokes. The resulting homogenate was centri-
fuged for 5 min at 1000 · g, after which the pellet was rehomogenized
in 4.0 ml TES-buﬀer with 10 strokes and then recombined with the
1000 · g supernatant. The homogenate was centrifuged for 10 min at
100 · g. The pellet (P1) was resuspended in 300 ll TES-buﬀer and
saved. The supernatant was centrifuged for 10 min at 5000 · g. The
pellet (P2) was resuspended in 300 ll TES buﬀer and saved. The super-
natant was centrifuged for 20 min at 20000 · g. The pellet (P3) was
resuspended in 300 ll TES-buﬀer and saved. The supernatant was cen-
trifuged for 30 min at 48000 · g. The pellet (P4) was resuspended in
150 ll TES-buﬀer and saved. The supernatant was centrifuged for
65 min at 250000 · g. The pellet (P5) was resuspended in 150 ll
TES-buﬀer and saved. Upon analysis of P1–P5 with ouabain-sensitive
p-nitrophenyl-phosphatase and with EGTA-sensitive Ca2+-ATPase,it
has been established that fractions P2 refers as PM-fraction and P5
as LDM fraction [13–16,33].
2.2.3. Western blotting. FAT/CD36 and FABPpm protein expres-
sions were determined in cardiac myocytes and perfused intact hearts.
For these purposes cardiac myocytes were washed twice with PBS buf-
fer, homogenized and resuspended in Buﬀer 2 (Tris-base 10 mM,
EDTA 1 mM, pH 7.4) and frozen in liquid nitrogen. From perfused
hearts homogenates yielding crude membranes were prepared as de-
scribed previously [13,33]. FAT/CD36 and FABPpm were also deter-
mined in PM and LDM fractions from subfractionated cardiac
myocytes, as well as in PM and LDM obtained from perfused hearts.
For other proteins, cardiac myocytes at the end of the incubation per-
iod were washed twice with ice-cold PBS buﬀer. Proteins were ex-
tracted with extraction buﬀer (in mM: 50 Tris-acid base (pH 7.5), 1
EDTA, 1 EGTA, 1 sodium ortovanadate, 50 NaF, 5 sodium pyro-
phosphate, 270 sucrose, 1 DTT, 1% Triton X-100, 5 lg ml leupeptin,
5 lg/ml pepstatin) as described [13,33]. The supernatant fraction was
collected after centrifugation at 10000 · g, for 10 min. at 4 C and fro-
zen in liquid nitrogen for protein assay and Western blot protocols.
Routine Western blotting procedures were used to detect proteins as
described previously [13–16]. Protein content was determined with
bicinchonic acid method with BSA serving as a protein standard Sig-
nals obtained by Western blotting were quantiﬁed by densitometry
(SynGene, ChemiGenius2, Perkin–Elmer, Boston, ON).PA
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Fig. 1. Eﬀects of hypoxia (15 min) on (A) the initial rates of palmitate u
(C) myocardial glycogen utilization in Langendorﬀ perfused hearts. Data
(means ± S.E.M.). *P < 0.05, hypoxia vs. control.All data are expressed as means ± S.E.M. Statistical diﬀerence be-
tween groups was tested with analyses of variance and appropriate
post hoc tests, or with a t-test. Statistical signiﬁcance was set at
P 6 0.05.3. Results
3.1. Eﬀects of hypoxia on the rates of LCFA uptake and
metabolism
During hypoxia, (15 min) the initial rate of palmitate uptake
by cardiac myocytes was increased (+40%, P < 0.05, Fig. 1A).
In contrast, the rate of palmitate oxidation during acute hy-
poxia was reduced (35%, P < 0.05, Fig. 1B). Acute hypoxia
induced also a reduction in myocardial glycogen (24%,
P < 0.05, Fig. 1C).
Hypoxia (15 min) increased palmitate incorporation into
phospholipids (+48%, P < 0.05, Fig. 2A) and into the intracel-
lular triacylglycerol depot (+28%, P < 0.05, Fig. 2A). Acute
hypoxia induced a parallel increase in palmitate incorporation
into ceramides (+21%, P < 0.05, Fig. 2B). No signiﬁcant
changes in other lipid fractions were observed. Total lipid
accumulation, calculated as the sum of all neutral lipid frac-
tions, was also increased (+26%, P < 0.05, Fig. 2C).
3.2. Eﬀects of hypoxia on the subcellular distribution of fatty
acid transporters (FAT/CD36, FABPpm)
Hypoxia (15 min) did not alter the total protein expression
of FAT/CD36 and FABPpm, either in isolated cardiac myo-
cytes or in intact, perfused hearts (data not shown). However,
incubation of cardiac myocytes under hypoxic conditions in-
duced the translocation of FAT/CD36 from the LDM
(25%, P < 0.05) to the PM (+54%, P < 0.05) in cardiac myo-
cytes (Fig. 3A). We also observed a hypoxia-induced increase
in FABPpm at the PM (+56%, P < 0.05) and a concomitant
FABPpm reduction in the LDM (24%, P < 0.05) in cardiac
myocytes (Fig. 3B). Importantly, in intact Langendorﬀ per-
fused hearts, a more physiological preparation, hypoxia also*
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Fig. 4. Representative Western blots showing the eﬀects of hypoxia on
the phosphorylation of AMPK (Thr172), ERK1/2 (Thr202/Thr204)
and pAkt (Ser473) proteins in cardiac myocytes. The same quantity of
protein (30 lg) is loaded into each well and check for equal loading
after transfer with Ponceau stain. Similar results were observed in three
independent experiments. Insulin eﬀects are included as a positive
control.
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to the PM (+66% and +61%, respectively, P < 0.05, Fig. 3A
and B), with a concomitant decline in FAT/CD36 and FAB-
Ppm in the LDM (24% and 23%, P < 0.05, Fig. 3A and B).
3.3. Eﬀects of hypoxia on signaling pathways in cardiac
myocytes
We examined possible signaling pathways activated by acute
hypoxia (15 min) in cardiac myocytes. As has been shown pre-
viously [24,33], exposure of cardiac myocytes to hypoxia in-
creased the AMPK phosphorylation (Fig. 4). Hypoxia did
not induce the phosphorylation of ERK1/2 nor Akt (Fig. 4).
As a positive control, acute exposure of cardiac myocytes to
insulin (10 nM, 15 min) did stimulate the phosphorylation of
Akt ERK1/2, as expected [35–37].4. Discussion
In the present study we conﬁrmed that hypoxia reduced
palmitate oxidation and this was associated with an increase
in palmitate incorporation into selected lipid depots (phospho-
lipids, triacylglycerols and ceramides). In addition, we have the
novel ﬁndings that: (a) during hypoxia the initial rate of palm-
itate uptake is upregulated, and that (b) this is associated with
a concomitant hypoxia-induced translocation of the fatty acid
transporters FAT/CD36 and FABPpm from low density
microsomes, an intracellular depot, to the plasma membrane.
Given that hypoxia activated AMPK [34], and based on our
previous work [15,16,33], we propose that the hypoxia-induced
activation of AMPK is the molecular mechanism that stimu-
lates the translocation of the fatty acid transporters from their
intracellular depots to the cell surface. Thus, the present stud-
ies have shown that an increased rate of LCFA transport, as
well the previously known reduction in LCFA oxidation, both
contribute to the intramyocardial accumulation of lipids in the
hypoxic heart.
It is well known that myocardial lipid accumulation during
hypoxia could be at least partially due to the switch in energy
substrate preference from predominantly the oxidation of fatty
acids to the increased utilization of glucose [38–40]. Acutehypoxia accelerates also the glycogen breakdown as an alter-
native energy source [41]. Previously, it has been shown that
in the ischemic myocardium fatty acids are diverted from b-
oxidation into deposition as tissue lipids [17,18,42]. Our study
concurs with these observations, as we observed both a de-
creased rate of palmitate oxidation, increased glycogen utiliza-
tion and a concomitant increase in the deposition of fatty acids
into myocardial phospholipid and triacylglycerol depots dur-
ing acute hypoxia.
In the present study accumulation of fatty acids in the PL
and TG depots may be surprising. This may be expected to re-
duce intracellular ATP levels, since esteriﬁcation of fatty acids
is energetically expensive, and ATP is already reduced during
hypoxia [43]. However, removing fatty acids from cytosol
could also be beneﬁcial, since high concentrations of myocar-
dial fatty acids may be detrimental to the cardiac myocytes
[44–47]. Nonetheless, elevated myocardial triglycerides and
ceramides in obese Zucker diabetic rats have been associated
with the development of cardiac dilatation and reduced con-
tractility [48]. Moreover, accumulation of intracellular cera-
mide concentrations alone have been also associated with
myocardial damage [49], and ceramide accumulation is known
to occur in hearts during ischemia/reperfusion [50,51]. Thus, it
seems that removing fatty acids from the cytosol into triacyl-
glycerol depots and ceramides during hypoxia cannot be seen
as being beneﬁcial. It is likely that the greater incorporation
of fatty acids into lipid depots reﬂects a mass action eﬀect
due to increased uptake of LCFA into the cell and the dimin-
ished rate of LCFA oxidation during hypoxia.
Recent studies in cardiac myocytes have demonstrated that
protein-mediated LCFA transport across plasma membranes
is a highly regulated process involving changes in the sarcolem-
mal content of fatty acid transporters [13–16]. Speciﬁcally,
insulin induced the translocation of FAT/CD36 only, while
contraction-like stimuli (AICAR and oligomycin) induced
the redistribution of both FAT/CD36 and FABPpm from an
intracellular pool to the plasma membrane [13–16]. These in-
crease in plasmalemmal fatty acid transporters, whether in-
duced by insulin or by contraction-mimetic signals, increased
the rate of LCFA transport [13–16,33]. Therefore, an impor-
tant aspect of the present study was to establish whether the
hypoxia-induced changes in the initial rates of LCFA uptake
by cardiac myocytes also resulted in redistribution of the
LCFA transporters to the plasma membranes. In the present
study, we have shown for the ﬁrst time, in isolated cardiac
myocytes as well as in the intact perfused heart, that hypoxia
induced the translocation of both FAT/CD36 and FABPpm
from an intracellular pool to the plasma membrane, an eﬀect
that was not attributable to the increased expression of these
proteins (data not shown). It is likely that the redistribution
of FAT/D36 and FABPpm to the plasma membranes in hyp-
oxic cardiac myocytes and hypoxic hearts can be attributed to
the hypoxia-induced AMPK activation, since we (present
study) and others [34,46,47,52] have observed that myocardial
hypoxia triggers the activation of AMP-kinase, and since we
have previously shown that AMPK activation redistributes
FAT/CD36 and FABPpm to the plasma membrane [16,33].
Previous studies from our laboratories have shown that rates
of LCFA uptake are increased whenever the plasmalemmal
content of fatty acid transporters is increased, and conversely
that the rate of LCFA transport is reduced when the plasma-
lemmal content of fatty acid transporters is decreased
3622 A. Chabowski et al. / FEBS Letters 580 (2006) 3617–3623[13–16,53,54]. Thus, the hypoxia-induced increase in the initial
rate of LCFA uptake is most likely attributable to the hypoxia-
induced translocation of LCFA transporters to the plasma
membrane.5. Conclusions
In present study we have provided several novel observa-
tions. First, we have shown that acute hypoxia induces the
redistribution of FAT/CD36 and FABPpm from an intracellu-
lar pool to the plasma membranes, an eﬀect that was most
likely triggered by the activation of AMPK in the hypoxic
myocyte. Second, the translocation of the LCFA transporters
to the plasma membrane increased the initial rates of LCFA
uptake into cardiac myocytes in proportion to the increase in
the plasmalemmal content of two fatty acid transporters
(FAT/CD36 and FABPpm). A quantitatively similar, hypox-
ia-induced translocation of FAT/CD36 and FABPpm was ob-
served in intact perfused heart. Finally, the rates of fatty acid
oxidation were also reduced in the hypoxic heart while fatty
acid incorporation into PL, TG and ceramides was increased.
Thus, our data indicate that the increased intracellular lipid
accumulation in hypoxic hearts is attributable to: (a) not only
a reduced rate of fatty acid oxidation, as had been shown else-
where, but also to (b) an increased rate of fatty acid transport
into the heart, the latter being attributable to a hypoxia-med-
iated activation of AMPK which induces translocation of fatty
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